Fate Therapeutics (FATE)
(Real Time Quote from BATS)
$3.78 USD
-0.09 (-2.33%)
Updated Apr 26, 2024 02:37 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Average Brokerage Rating
Current ABR | 2.57 |
ABR (Last week) | 2.57 |
# of Recs in ABR | 21 |
Average Target Price | $7.57 |
LT Growth Rate | 7.90% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -0.48 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 13 | 13 | 13 | 13 | 13 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.57 | 2.57 | 2.57 | 2.57 | 2.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/23/2024 | Wedbush Securities | David M Nierengarten | Hold | Hold |
4/11/2024 | Needham & Company | Gil J Blum | Hold | Hold |
3/1/2024 | H.C. Wainwright & Co. | Robert Burns | Hold | Hold |
2/27/2024 | BMO Capital Markets | Etzer Darout | Hold | Hold |
2/27/2024 | Cantor Fitzgerald & Co | Li Watsek | Hold | Hold |
12/1/2023 | Guggenheim Securities | Michael Schmidt | Hold | Hold |
11/29/2023 | Robert W. Baird & Co. | Jack K Allen | Hold | Hold |
9/28/2023 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
9/15/2023 | Canaccord Genuity | William Maughan | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.